BREAKING: Futures Await Nvidia Earnings Eli Lilly (ELI) partner and cancer treatment developer Rigel Pharmaceuticals (RIGL) is nearing a buy point of a cup base. The drug stock got a boost after Rigel reported strong third-quarter earnings and raised its sales guidance in early November. The IBD 50 Growth Stocks To Watch has outperformed 94% of stocks that Investor's Business Daily tracks with its 152%… Related news Rigel Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating IBD Videos Ge ...